formulation for stability: moving beyond excipient ...€¦ · moving beyond excipient...

18
[email protected] 2018 1 Kenneth C. Waterman, Ph.D. FreeThink Technologies, Inc. Branford, CT USA Formulation for Stability: Moving Beyond Excipient Compatibility

Upload: others

Post on 09-Oct-2020

26 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 1

Kenneth C. Waterman, Ph.D.

FreeThink Technologies, Inc.

Branford, CT USA

Formulation for Stability: Moving Beyond Excipient Compatibility

Page 2: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 2

• Some degradation due to direct excipient-drug reaction

• Example: Maillard reaction between secondary amines (amino acids) and reducing carbohydrates (e.g., lactose)—leads to brown colors + multiple products

• Relatively uncommon (other than this reaction)

Reactive Excipients

Page 3: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 3

Reaction with Excipient Impurities/Degradants

• Peroxides

• Formaldehyde (and other aldehydes)

• Acids

• Formic acid

• Acetic acid

Page 4: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 4

• Effects proportional to interfacial contact

• Specific degradation will show different effects

• Some degradation mechanisms will be more sensitive than others to excipients

Non-reactive Excipient Impact

Page 5: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 5

• Impact of concentration (approximation):

log 𝑘 = 𝛼𝑙𝑜𝑔100%

%𝑎𝑐𝑡𝑖𝑣𝑒+ 𝑙𝑜𝑔𝑘0

• α may be independent of temperature/RH• α may depend on T/RH (catalysis)

Drug Concentration Impact in Solid Formulations

Page 6: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 6

Example

CP-481715 tablets

From J Pharm Sci 2012, 101, 4170-4177.

Page 7: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 7

G. Scrivens; 2017 Presentation from Science of Stability Conference

Mixed with MCC

Example

Page 8: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 8

Prasugrel Pediatric

Example

A. Dill; 2015 Presentation from Science of Stability Conference

1.7 2.0 2.2 2.4 2.6 2.8log(100%/%API)

25°C

30°C

40°C

-1.3

-0.9

-0.4

0

0.4

log

k

Page 9: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 9

Excipient Compatibility

• Binary blend stability (often rank order)• 1:1 API:Excipient• Representative API level:Excpient level

Page 10: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 10

Problems with Binary Excipient Compatibility

• For low level excipient, greatly exaggerates issues• Often leads to excluding magnesium stearate

• Since true interaction is base on log-log scaling, formulation stability is not a weighted average of the binary stabilities

• Rank order not appropriate• Excludes good enough excipients

• Stability studies can be slow delaying product development

Page 11: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

Copyright FreeThink Technologies, Inc. 2018 freethinktech.com

11

Screening Stability (Rank Order)Two formulations screened 2 weeks, 70°C/75%RH

Formulation 70°C

A 0.18

B 0.90

Which formulation should you proceed with for ambient (25°C/60%RH) storage?

Page 12: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

Copyright FreeThink Technologies, Inc. 2018 freethinktech.com

12

-7

-6

-5

-4

-3

-2

-1

0

0.0029 0.003 0.0031 0.0032 0.0033 0.0034

ln k

1/T

70°C

60°C

50°C

25°C

B

A

Longer shelf-life

Page 13: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

Copyright FreeThink Technologies, Inc. 2018 freethinktech.com

13

• Rank order from high temperature often opposite to room temperature

• Rank order does not distinguish formulations that are all good or all bad

Screening Stability (Rank Order)

Page 14: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 14

Excipient Compatibility Formulation Development(Real Time Stability)

API-excipient binary blends

Use data to design formulations

Develop final formulation

3-6 mo 3-6 mo

Traditional Formulation Development: 6-12 mos.

Long development time for stable formulations

Page 15: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 15

Rapid Formulation Development: ASAPprime® Tiered Approach

• Full formulations prepared (e.g., tablets, capsules) • 3-4 Tier 1 full formulations• Low API concentration (worst case)

• ASAP studies conducted• Tier 1 formulations work for most APIs and enable

fast development• If Tier 1 fails, Tier 2 formulations used• Rare that we need to go past this• Must justify formulation used: do not need

excipient compatibility for regulatory submissions.

Page 16: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 16

Rapid Formulation Development

2-3 1st tier formulations

Develop final formulation

2-3 2nd tier formulations

Develop final formulation

2-3 3rd tier formulations Develop final

formulation

ASAP-Based Formulation Development using Tiers: 1-4 mos.

Page 17: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 17

Example Tier 1 Tablet Formulations

Function Ingredient Formulation 1 wt%

Formulation 2 wt%

Active API 5 5

Diluent (ductile) MCC 54 54

Diluent (brittle) Lactose 25

Diluent (brittle) Mannitol 25

Disintegrant Croscarmellose sodium 10

Disintegrant Crospovidone 10

Binder HPC 5

Binder Povidone 5

Lubricant Magnesium stearate 1

Lubricant Stearic acid 1

Page 18: Formulation for Stability: Moving Beyond Excipient ...€¦ · Moving Beyond Excipient Compatibility. ken.waterman@freethinktech.com 2018 2 • Some degradation due to direct excipient-drug

[email protected] 2018 18

Tiered Approach to Formulation Development

Advantages to ASAP Approach

• Fewer resources, much shorter time-line• Most cases can go straight to experienced

(manufacturable) formulation (and processing) space

• Does not rule out effective excipients based on rank-order or exaggerated binary results